Michael H. Davidson

Michael H. Davidson's AcademicInfluence.com Rankings

Michael H. Davidson

Medical

#1716

World Rank

#2086

Historical Rank

Cardiology

#136

World Rank

#139

Historical Rank

medical Degrees

Michael H. Davidson

Philosophy

#5189

World Rank

#7925

Historical Rank

Logic

#2507

World Rank

#3511

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Michael H. Davidson's Degrees

Doctorate Medicine Harvard University

Why Is Michael H. Davidson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael H. Davidson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). (2002) (1878)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). (2003) (1360)
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. (1999) (916)
Lipoprotein Management in Patients With Cardiometabolic Risk (2008) (796)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. (2006) (681)
Safety of anacetrapib in patients with or at high risk for coronary heart disease. (2010) (610)
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. (2008) (559)
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. (2008) (554)
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. (2002) (533)
Risk for myopathy with statin therapy in high-risk patients. (2003) (467)
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. (1995) (459)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. (2006) (427)
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. (1996) (422)
AACE comprehensive diabetes management algorithm 2013. (2013) (401)
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. (2005) (398)
Effect of ACAT inhibition on the progression of coronary atherosclerosis. (2006) (387)
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. (2007) (371)
Safety considerations with fibrate therapy. (2007) (370)
Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. (2006) (368)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. (2020) (331)
Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. (1992) (308)
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. (2000) (305)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (299)
High-density lipoproteins: a consensus statement from the National Lipid Association. (2013) (293)
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. (2005) (288)
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. (1999) (286)
Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women: Beyond Endorsed Lipid Lowering With EBT Scanning (BELLES) (2005) (278)
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. (2011) (264)
Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. (2002) (253)
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. (1999) (253)
The Hypocholesterolemic Effects of β-Glucan in Oatmeal and Oat Bran: A Dose-Controlled Study (1991) (252)
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. (1998) (246)
Diagnosis and treatment of familial hypercholesterolaemia. (2013) (243)
AACE/ACE comprehensive diabetes management algorithm 2015. (2015) (243)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. (2008) (238)
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. (1997) (236)
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. (2002) (228)
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications (2008) (227)
Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis (2002) (223)
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. (2013) (218)
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. (2013) (205)
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. (2001) (198)
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. (2014) (198)
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? (2012) (195)
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. (2014) (183)
Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. (2001) (182)
Safety of aggressive lipid management. (2007) (175)
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. (2008) (171)
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. (2012) (169)
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. (1997) (168)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (167)
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. (2008) (158)
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. (2000) (157)
Hypertriglyceridemic Waist Phenotype Predicts Increased Visceral Fat in Subjects With Type 2 Diabetes (2009) (154)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. (2006) (150)
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial (2018) (150)
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. (2001) (148)
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. (2009) (147)
Effects of dietary inulin on serum lipids in men and women with hypercholesterolemia (1998) (146)
Cardiovascular outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) (2002) (140)
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. (2011) (139)
The use of high-sensitivity assays for C-reactive protein in clinical practice (2008) (135)
Statin safety: an assessment using an administrative claims database. (2006) (134)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. (2006) (131)
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. (2001) (130)
Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. (2009) (129)
Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes (2008) (128)
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. (2013) (127)
The safety and immunogenicity of a CETP vaccine in healthy adults. (2003) (127)
Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus (2008) (119)
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. (2008) (118)
Comparative effects of lipid-lowering therapies. (2004) (116)
Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. (2007) (113)
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. (2009) (108)
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients* (2006) (107)
Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. (1999) (107)
Combination therapy for dyslipidemia: safety and regulatory considerations. (2002) (107)
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). (2013) (106)
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. (2000) (106)
Relation of Abdominal Fat Depots to Systemic Markers of Inflammation in Type 2 Diabetes (2009) (106)
Statin safety: an appraisal from the adverse event reporting system. (2006) (105)
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. (2006) (101)
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. (2000) (100)
A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. (1996) (95)
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. (2009) (94)
Effects of dietary inulin on serum lipids. (1999) (92)
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. (2005) (91)
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). (2008) (89)
Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated? (2009) (88)
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. (2001) (86)
Reductions in Atherogenic Lipids and Major Cardiovascular Events (2016) (85)
Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. (1999) (84)
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. (2009) (84)
Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. (1998) (84)
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. (2001) (83)
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia (2002) (83)
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. (2014) (83)
Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid (2013) (82)
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Compete (2009) (82)
Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons Learned (2002) (82)
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia (2008) (81)
High-density lipoprotein metabolism: potential therapeutic targets. (2007) (81)
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. (1997) (81)
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. (2003) (79)
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions (2006) (77)
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. (1999) (77)
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. (1997) (77)
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). (2003) (76)
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance (2004) (75)
Cardiovascular effects of glucagonlike peptide-1 agonists. (2011) (75)
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. (2009) (74)
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. (2000) (73)
Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol (2005) (71)
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. (2020) (71)
Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients (1998) (70)
Clinical significance of statin pleiotropic effects: hypotheses versus evidence. (2005) (70)
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study (2013) (69)
Measurement of Reverse Cholesterol Transport Pathways in Humans: In Vivo Rates of Free Cholesterol Efflux, Esterification, and Excretion (2012) (68)
Pharmacokinetic interactions between statins and fibrates. (2005) (66)
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. (2009) (66)
Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. (1998) (65)
The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. (1990) (64)
Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial (1996) (64)
Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. (2003) (61)
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). (2011) (60)
Differences between clinical trial efficacy and real-world effectiveness. (2006) (59)
Controversy surrounding the safety of cerivastatin (2002) (59)
Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST) (2014) (58)
ω-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps (2018) (57)
Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. (2003) (55)
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S] (2013) (55)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. (2019) (54)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial) (2003) (54)
Safety Profiles for the HMG-CoA Reductase Inhibitors (2012) (52)
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. (1994) (52)
A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. (1998) (51)
Lipid-lowering effects of statins: a comparative review (2006) (50)
Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men. (2007) (50)
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. (1995) (49)
Does differing metabolism by cytochrome P450 have clinical importance? (2000) (49)
A review of lipid management in primary and secondary prevention. (2009) (48)
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction (2006) (48)
Overcoming toxicity and side-effects of lipid-lowering therapies. (2014) (47)
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. (2015) (47)
Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. (1989) (47)
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. (2000) (47)
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. (2011) (47)
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. (1996) (47)
Striated muscle safety of ezetimibe/simvastatin (Vytorin). (2006) (47)
High-molecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. (2000) (46)
Incorporation of Lean Red Meat into a National Cholesterol Education Program Step I Diet: A Long-Term, Randomized Clinical Trial in Free-Living Persons with Hypercholesterolemia (2000) (46)
Update on CETP inhibition. (2010) (46)
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. (2010) (45)
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial (2015) (45)
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. (2000) (45)
Niacin use and cutaneous flushing: mechanisms and strategies for prevention. (2008) (44)
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. (2009) (44)
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis (2020) (44)
Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. (2003) (44)
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. (2013) (42)
A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides (2020) (42)
Ethnic differences in achievement of cholesterol treatment goals (2006) (41)
Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. (2008) (41)
Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins. (1997) (40)
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. (2006) (40)
Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. (1999) (40)
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Compete (2009) (39)
ETC-1002: a future option for lipid disorders? (2014) (39)
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. (2021) (39)
Cholesterol absorption blockade with ezetimibe. (2005) (39)
Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia (2008) (38)
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. (2013) (38)
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial ☆ ☆☆ (2001) (38)
Novel nonstatin strategies to lower low-density lipoprotein cholesterol (2009) (37)
Relationship of Traditional and Nontraditional Cardiovascular Risk Factors to Coronary Artery Calcium in Type 2 Diabetes (2007) (36)
Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. (2002) (36)
Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia (2000) (36)
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review (2007) (36)
Ezetimibe: a novel option for lowering cholesterol (2003) (36)
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia (2005) (35)
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins (2008) (34)
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. (2008) (34)
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. (2005) (34)
Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. (2004) (34)
Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. (2012) (33)
Novel targets that affect high-density lipoprotein metabolism: the next frontier. (2009) (32)
Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia (2003) (32)
Squalene synthase inhibition: A novel target for the management of dyslipidemia (2007) (32)
A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. (2002) (31)
High-density lipoproteins: marker of cardiovascular risk and therapeutic target. (2010) (30)
Novel developments in omega-3 fatty acid-based strategies (2011) (30)
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. (1992) (29)
Type 2 diabetes and cardiovascular disease: reducing the risk. (2007) (29)
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. (2000) (29)
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. (2010) (28)
A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin (1996) (28)
Lipid responses to consumption of a beta-glucan containing ready-to-eat cereal in children and adolescents with mild-to-moderate primary hypercholesterolemia (2003) (28)
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport (2004) (27)
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. (2010) (27)
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). (2013) (27)
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. (2020) (27)
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. (2008) (27)
Combination therapy in the management of complex dyslipidemias (2004) (26)
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. (2008) (26)
Marine oil capsule therapy for the treatment of hyperlipidemia. (1991) (26)
Torcetrapib/atorvastatin combination therapy (2005) (26)
Use of A Treatment Algorithm to Achieve NCEP ATP III Goals With Atorvastatin (2005) (25)
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. (1994) (25)
Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older (2007) (25)
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. (2008) (24)
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. (2000) (24)
A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia (2010) (24)
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. (2003) (24)
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. (2015) (24)
Lp-PLA2: A New Target for Statin Therapy (2010) (23)
Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. (2013) (23)
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. (2018) (23)
Medical and cost burden of atherosclerosis among patients treated in routine clinical practice (2010) (23)
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy (2002) (23)
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. (2002) (23)
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. (2017) (23)
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus (2010) (22)
Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women (2001) (22)
Management of Hypercholesterolaemia in Postmenopausal Women (2002) (22)
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. (2009) (22)
Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. (2008) (22)
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. (2016) (22)
Peripheral artery disease, biomarkers, and darapladib. (2011) (22)
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. (2006) (22)
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. (2012) (21)
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals (2007) (21)
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. (2014) (21)
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. (1997) (21)
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. (2007) (21)
Statin and ezetimibe combination therapy in cardiovascular disease (2009) (21)
Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance (2013) (21)
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. (2009) (21)
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. (2001) (20)
Management of dyslipidemia in patients with complicated metabolic syndrome. (2005) (20)
Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy (2015) (20)
Evidence for altered positional specificity of LCAT in vivo: studies with docosahexaenoic acid feeding in humans. (2004) (20)
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). (2018) (20)
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. (2013) (19)
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? (2016) (19)
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. (2007) (18)
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. (2011) (18)
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. (2008) (17)
The editor's roundtable: the JUPITER trial--initial results and clinical implications. (2009) (17)
Possible differences between fibrates in pharmacokinetic interactions with statins. (2003) (17)
Omega-3 Free Fatty Acids Demonstrate More Than 4-Fold Greater Bioavailability for EPA and DHA Compared with Omega-3-acid Ethyl Esters in Conjunction with a Low-Fat Diet: The ECLIPSE Study† (2011) (17)
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. (2001) (16)
Efficacy of over-the-counter nutritional supplements (2003) (16)
Ezetimlbe co-administered With slmvastatin in 668 patients With primary hypercholesterolemia (2002) (15)
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. (2012) (15)
Bioavailability of Eicosapentaenoic and Docosahexaenoic n-3 Polyunsaturated Fatty Acids in Salmon Patties Compared with Capsules (2003) (15)
Therapies Targeting Exogenous Cholesterol Uptake: New Insights and Controversies (2011) (15)
Efficacy of the National Cholesterol Education Program Step I diet. A randomized trial incorporating quick-service foods. (1996) (15)
Cardiorenal Safety of OTC Analgesics (2018) (15)
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. (2013) (15)
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. (1997) (15)
New concepts in dyslipidemia in the metabolic syndrome and diabetes. (2006) (15)
Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events (2003) (15)
Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions (2001) (15)
Heart and estrogen/progestin replacement study follow-up (HERS-II) 1. Cardiovascular outcomes during 6.8 years of hormone therapy (2002) (14)
Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis (2015) (14)
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. (2019) (14)
Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus (2014) (14)
The future of n-3 polyunsaturated fatty acid therapy (2016) (14)
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. (1998) (14)
Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. (2015) (13)
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C (2018) (13)
Global risk management in patients with type 2 diabetes mellitus. (2007) (13)
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. (2008) (13)
Can We Cure Atherosclerosis? (2018) (13)
Apolipoprotein A-I therapy promise, challenges, and disappointment. (2011) (13)
Cholesterol-Lowering Drugs Bring Benefits to High-Risk Populations Even When LDL Is Normal (2003) (12)
Updating the assessment of cardiac risk: beyond Framingham. (2009) (12)
Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial (2012) (12)
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. (2009) (12)
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial (2022) (12)
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. (2005) (12)
The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients (1998) (12)
HDL and CETP Inhibition: Will This DEFINE the Future? (2012) (12)
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk (2012) (12)
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers (2017) (11)
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. (2005) (11)
Focusing on high-density lipoprotein for coronary heart disease risk reduction. (2011) (11)
Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. (2000) (11)
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia (2016) (11)
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention (2015) (11)
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia (2014) (10)
ETC-1002 LOWERS LDL-C AND BENEFICIALLY MODULATES OTHER CARDIO-METABOLIC RISK FACTORS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH EITHER NORMAL OR ELEVATED TRIGLYCERIDES (2012) (10)
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. (2009) (10)
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. (1997) (10)
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. (2001) (10)
Antioxidants and lipid metabolism. Implications for the present and direction for the future. (1993) (10)
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. (1995) (10)
Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials (2018) (10)
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women (2012) (10)
The Incremental Value of Lipids and Inflammatory Biomarkers in Determining Residual Cardiovascular Risk (2011) (10)
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. (2005) (10)
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. (2013) (10)
The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. (2008) (10)
One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia (2012) (9)
Colesevelam HCl (Welchol™), a new, potent, well tolerated, non systemic, lipid lowering agent (2000) (9)
Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients with Severe Hypertriglyceridemia and Changes Correlate with Increases in LDL-C: A Sub-analysis of the EVOLVE trial (2012) (9)
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. (2009) (9)
Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport (2007) (9)
A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial (2001) (9)
Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. (2008) (9)
Colesevelam HCl Decreases Atherosclerosis and May Activate Reverse Cholesterol Transport in Cholesterol-Fed Rabbits (2006) (9)
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. (2007) (9)
Is it over for ezetimibe? (2008) (9)
Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk† (2012) (8)
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. (2008) (8)
SAFETY AND EFFICACY OF MIPOMERSEN ADMINISTERED AS ADD-ON THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CARDIOVASCULAR RISK (2011) (8)
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. (2003) (8)
Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure? (2012) (8)
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. (2006) (7)
PITAVASTATIN 4 MG PROVIDES SIGNIFICANTLY GREATER REDUCTION IN LDL-C COMPARED TO PRAVASTATIN 40 MG WITH NEUTRAL EFFECTS ON GLUCOSE METABOLISM: PRESPECIFIED SAFETY ANALYSIS FROM THE SHORT-TERM PHASE 4 PREVAIL US TRIAL IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA (2012) (7)
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels. (2008) (7)
High-dose statin therapy: benefits and safety in aggressive lipid lowering. (2008) (7)
Rosuvastatin in Elderly Patients (2007) (7)
Lipid management and the elderly. (2003) (7)
Pioglitazone Versus Glimepiride on Coronary Artery Calcium Progression in Patients With Type 2 Diabetes Mellitus: A Secondary End Point of the CHICAGO Study (2010) (7)
A look to the future: new treatment guidelines and a perspective on statins. (2002) (7)
Atherosclerosis surrogate imaging trials come of age: For better or for worse? (2008) (7)
High-dose statins in acute coronary syndromes. (2005) (6)
Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data* (2007) (6)
Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia (2001) (6)
Pharmacotherapy: Implications of high-dose statin link with incident diabetes (2011) (6)
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction. (2002) (6)
Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. (2018) (6)
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu. (2011) (6)
The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. (2011) (5)
Retrospective Comparison of the Effectiveness of a Fenofibrate 145 mg Formulation Compared with the Standard 160 mg Tablet (2008) (5)
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution (2013) (5)
How I treat statin-associated side effects in an outpatient setting. (2021) (5)
205: ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed Dyslipidemia (2008) (5)
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients (2018) (5)
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention (2018) (5)
Pharmacological Therapy for Cardiovascular Disease (2007) (5)
Pitavastatin 4 Mg Significantly Reduces LDL-P and Increases HDL Size Compared with Pravastatin 40 mg: Results from PREVAIL US (2012) (5)
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). (2006) (5)
Comparison of the efficacy and safety of atorvastatin versus cerivastatin in patients with hypercholesterolemia (1999) (5)
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. (2012) (5)
Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease (2011) (4)
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. (2009) (4)
RECENT ADVANCES AND EMERGING THERAPIES IN MANAGEMENT OF DYSLIPIDEMIAS. (2020) (4)
Abstract 18484: Modest Potential Association Between Reductions in Lipoprotein(a) and Major Adverse Cardiovascular Events in the Phase 3 Trials of Alirocumab versus Control (2016) (4)
Combination lipid-lowering therapy in diabetes (2003) (4)
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. (2007) (4)
Abstract: 103 EFFECTS OF LOW DOSE MTP INHIBITION ALONE AND IN COMBINATION WITH OTHER LIPID-LOWERING DRUGS ON HEPATIC FAT AND PLASMA LIPIDS (2009) (4)
Abstract 193: Lapaquistat Acetate, A Novel Squalene Synthase Inhibitor, Co-administered with Atorvastatin Reduces Plasma Lipids and C-Reactive Protein Levels in Subjects with Primary Hypercholesterolemia (2007) (4)
Abstract 9649: Lipid-modifying Effects of Anacetrapib in Patients with Lower versus Higher Baseline Levels Of HDL-C, LDL-C, And TG: Pre-Specified Subgroup Analyses of the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) Trial (2011) (4)
Safety considerations with fibrate therapy. Commentary (2007) (4)
WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE (2011) (4)
Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes (2009) (4)
Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome (2018) (4)
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. (2008) (4)
Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. (2014) (4)
Abstract 16864: The Effect of Omega-3 Carboxylic Acids on Apolipoprotein CIII Containing Lipoproteins in Moderate to Severe Hypertriglyceridemia (2014) (4)
Effects of conjugated estrogens alone and combined with pravastatin for management of hypercholesterolemia in postmenopausal women (1996) (4)
Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern Europe. (2012) (4)
Biologic therapies for dyslipidemia (2004) (4)
Management of Severe Hypertriglyceridemia with a Novel Omega-3 Free- Fatty Acid Formulation: Subgroups in the EVOLVE Trial (2013) (4)
Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067. (2007) (4)
Focus on HDL as a therapeutic target for CAD risk reduction. (2009) (4)
Plasma Fatty Acids as Predictors of Triglyceride and Non-HDL Cholesterol Responses to Omega-3 Free Fatty Acid Therapy in Hypertriglyceridemia (2014) (3)
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. (2019) (3)
Role of statin therapy in the management of patients with the metabolic syndrome (2007) (3)
Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. (2016) (3)
Drugs in development for management of lipoprotein disorders. (2011) (3)
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels (2022) (3)
Evidence for altered positional specificity of LCAT in vivo Published, JLR Papers in Press, October 1, 2004. DOI 10.1194/jlr.M400197-JLR200 (2004) (3)
Recent Developments in the Treatment of Familial Hypercholesterolemia: A Review of Several New Drug Classes (2013) (3)
RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. (2014) (3)
Changing characteristics of statin-related cIMT trials from 1988 to 2006. (2016) (3)
Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia? (2006) (3)
Newer pharmaceutical agents to treat lipid disorders (2003) (3)
Abstract 3726: Risk Factors for Discontinuation of Statin Medications: Evidence From a Large National Pharmacy Claims Database (2007) (3)
How low to target LDL? (2006) (3)
RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2016) (2)
A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL) (2013) (2)
Should every patient with diabetes receive a statin? (2008) (2)
Medical management of patients before the incidence of a cardiovascular event. (2009) (2)
Efficacy of antiobesity therapies. (2000) (2)
The Role of Omega-3 Fatty Acids in Dyslipidemias (2015) (2)
Dalcetrapib in High-Risk Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome (2009) (2)
The efficacy of simvastatin in patients with hypertriglyceridemia (1999) (2)
Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis (2019) (2)
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. (2017) (2)
Effect of hydroxypropylmethylcellulose on serum lipids in subjects with mild-to-moderate primary hypercholesterolemia (1998) (2)
Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia (2002) (2)
Reducing residual cardiovascular risk with novel therapies. (2020) (2)
The editor's roundtable: JUPITER follow-up. (2011) (2)
RESULTS FROM THE FENOFIBRIC ACID ON CAROTID INTIMA-MEDIA THICKNESS IN SUBJECTS WITH TYPE IIB DYSLIPIDEMIA WITH RESIDUAL RISK IN ADDITION TO ATORVASTATIN THERAPY (FIRST) TRIAL (2013) (2)
Reducing the risk of stroke through appropriate targets and treatments. (2007) (2)
The role of genetics in cardiovascular risk reduction: Findings from a single lipid clinic and review of the literature. (2020) (2)
Undertreatment among high-risk dyslipidemic patients: results of a national survey of goal achievement for National Cholesterol Education Program Adult Treatment Panel III guidelines (2005) (2)
Therapeutic Lipidology (2021) (2)
Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis (2021) (2)
Abstract 52: Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels (2016) (2)
207: Aggressive Treatment With Atorvastatin Is Associated With Improvement in Renal Function in Managed Care Patients With Coronary Heart Disease (2007) (2)
Simvastatin and atorvastatin have different effects at high doses on high density lipoprotein cholesterol and apolipoprotein A-I (1999) (2)
Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. (2014) (2)
Comparative effects of marine and olive oil dietary supplementation on coronary risk factors (1989) (2)
Abstract: 1014 LONG-TERM EFFECT OF ADDING FENOFIBRIC ACID TO MODERATEDOSE STATIN ON C-REACTIVE PROTEIN LEVELS IN PATIENTS WITH MIXED DYSLIPIDEMIA (2009) (2)
Update on PCSK9 therapies for the treatment of dyslipidemia (2016) (2)
Omega-3 carboxylic acids in severe hypertriglyceridemia: EVOLVE II study results (2016) (2)
Treating dyslipidemia in high-risk patients: case reviews and discussion. (2004) (1)
Lipid altering efficacy of simvastatin in patients with hypertriglyceridemia (1999) (1)
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition (2022) (1)
A vasodilator stress MRI perfusion study: large HDL particle number is independently associated with microvascular function in patients with LDL-C <100mg/dL (2013) (1)
Abstract 3632: Increases in HDL-C in the CHICAGO Study Explain the Benefits of Pioglitazone in Reducing CIMT Progression in Patients With Type 2 Diabetes (2007) (1)
The Hypocholesterolemic Effects of β-Glucan-Reply (1991) (1)
Comparison of fluvastatin 80 mg extended-release and 40 mg immediate-release formulations (2000) (1)
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. (2020) (1)
Efficacy of combination cholestyramine and lovastatin therapy for the treatment of hypercholesterolemia (1991) (1)
Time-related trends in variability of cIMT changes in statin trials (2015) (1)
Pharmacological Approaches to Modifying HDL: More Basic Science to Understand HDL Metabolism is Necessary (2009) (1)
214: Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination with Rosuvastatin in Patients with Mixed Dyslipidemia: A Phase 3 Study (2008) (1)
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study (2020) (1)
Combination therapy with statins: who benefits? (2014) (1)
Low-Density Lipoprotein Cholesterol (2011) (1)
Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. (2016) (1)
Abstract 5069: Atorvastatin/Fenofibrate 40/100 mg Fixed-Dose Combination Tablet (LCP-AtorFen 40/100 mg) Offers Improved Efficacy Over 40 mg Atorvastatin and Higher Dose 145 mg Fenofibrate in Patients with Dyslipidemia (2008) (1)
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers (2017) (1)
THE HYPOCHOLESTEROLEMIC EFFECTS OF BETA -GLUCAN. AUTHORS' REPLY (1991) (1)
Reduction of LDL-C by more than 60% with the HMG-CoA reductase inhibitor atorvastatin (1994) (1)
Efficacy of starting doses of simvastatin vs pravastatin in elderly and non-elderly patients (1994) (1)
2.P.15 Two-year comparison of safety and efficacy of atorvastatin and lovastatin (1997) (1)
Poster abstractAtorvastatin, a new HMG-CoA reductase inhibitor (HMGRI), is safe and effective in hypertriglyceridemic patients (1994) (1)
Abstract: 1009 ADDITION OF NIACIN EXTENDED-RELEASE TO BASELINE STATIN TREATMENT REDUCES HSCRP IN PATIENTS WITH MIXED DYSLIPIDEMIA AND ELEVATED HSCRP (2009) (1)
Abstract 4162: Cardiovascular Event Reduction Associated with Achieving Optimal Values for Multiple Lipids (2006) (1)
CHAPTER 29 – Combination Therapy for Dyslipidemia (2009) (1)
The efficacy and safety of simvastatin 80 mg; Pooled results from worldwide clinical studies (1999) (1)
Efficacy and Safety of Ezetimibe Plus Rosuvastatin Versus Rosuvastatin Up-Titration in Hypercholesterolemic Patients at Risk for Atherosclerotic Coronary Heart Disease (2011) (1)
The Lipid-Lowering Effect of Lean Meat Diets Falls Far Short of That of Vegetarian Diets—Reply (2000) (1)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS (2017) (1)
Large and dose dependent effects of simvastatin 40 and 80 mg/day in combined hyperlipidemia (1999) (1)
Exploring the Lipid-Lowering Effects of Oats (1992) (1)
Abstract 1634: Effects of the DP1-receptor Antagonist MK-0524 on Nicotinic Acid-Induced Flushing in Lipid Clinic Patients (2006) (1)
Changes in Prescription Patterns for Ezetimibe/Simvastatin, Ezetimibe and Statin, and Statin Therapies and Expected Effects on LDL-C Reduction (2010) (1)
RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS (2016) (1)
Simultaneous Achievement of Optimal Lipid Levels with the Combination of Fenofibric Acid and Rosuvastatin in Patients with Mixed Dyslipidemia (2009) (1)
Cardiovascular Disease: Practical applications of the NCEP ATP III updates (2005) (1)
Abstract 4134: Beeswax Policosanol Failed to Demonstrate Lipid-Altering Effects in Well-Controlled Clinical Trials (2006) (1)
Abstract: P1390 DESIGN OF THE DEFINE TRIAL: DETERMINING THE EFFICACY AND TOLERABILITY OF CETP INHIBITION WITH ANACETRAPIB (2009) (0)
216: Incidence of Flushing Decreases Over Time During Long-Term Therapy with a Novel Combination of Niacin Extended-Release with Simvastatin (2008) (0)
Practical Steps to Improve Outcomes for Patients with Chronic Kidney Disease (CKD): A Whole Patient Approach (2013) (0)
In reply: The ENHANCE trial (July 2008) (2008) (0)
What Recent Trials Have Taught Us About the Efficacy of Ezetimibe (2020) (0)
Rosuvastatin: Just Another Statin? (2003) (0)
Managing cholesterol in the elderly (2006) (0)
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. (2012) (0)
Effects of Phytosterol Supplements on Hyperlipidemia: Case Series and Review of the Literature (2020) (0)
Abstract 192: Correlates of the Apolipoprotein C-III Response to the Addition of Prescription Omega-3 in Adults with Hypertriglyceridemia Despite Stable Statin Therapy (2007) (0)
A Clinical Puzzle: Fibrates and Homocysteine Elevation (2009) (0)
Statins Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega-3 Fatty Acids Emerging Drugs Summary (0)
Su-S1:3 The kidney and statin safety (2006) (0)
Abstract: P470 EFFICACY, SAFETY AND TOLERABILITY OF THE MTP INHIBITOR AEGR-733 COMBINED WITH ATORVASTATIN (2009) (0)
High-dose statins in acute coronary syndromes. Authors' replies (2005) (0)
PCV86 FLUSHING ASSESSMENT TOOL (FAST): PSYCHOMETRIC PROPERTIES OF A NEW MEASURE ASSESSING FLUSHING SYMPTOMS (2009) (0)
206: Long-Term Use of Colesevelam HCl Improves LDL-C and HDL-C Concentrations in Subjects with Primary Hypercholesterolemia (2008) (0)
Efficacy of low doses of simvastatin and niacin used concomitantly in patients with combined hyperlipidemia (1994) (0)
Simvastatin treatment in patients with type 2 diabetes and combined hyperlipidemia (1999) (0)
Abstract: P1444 ASPIRIN IN ADDITION TO NIACIN PROMOTES A MORE RAPID TOLERANCE TO FLUSHING (2009) (0)
217: Effects of Niacin Extended-Release/Simvastatin Versus Simvastatin Monotherapy on Plasma Lipids in Patients with or without High Baseline Triglycerides (2008) (0)
Use of combination therapy in a patient with complex dyslipidemia (2006) (0)
Combined dyslipidemia with a focus on current and emerging therapeutic approaches (2011) (0)
Abstract 17223: Compositional Lipoprotein Changes With Omega-3 Carboxylic Acids in Patients With Hypertriglyceridemia Paired With Low HDL-C: A Substudy From the ESPRIT Trial (2015) (0)
Comprar Therapeutic Lipidology | Davidson, Michael | 9781603272445 | Springer (2007) (0)
Abstract 426: The Remodeling of HDL-SAA by Macrophage Surface Heparan Sulfate is Necessary for Efficient Cholesterol Efflux (2014) (0)
Chapter 26 – Pharmacologic Therapy for Hypertriglyceridemia and Low HDL: Rationale for Combination Therapy (2007) (0)
Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab (2016) (0)
Intensive statin therapy in India: Demonstrating efficacy and safety (2016) (0)
Should Niacin Be the Preferred Drug to Add to a Statin? (2010) (0)
Abstract 14177: Prognostic Value of Normal Regadenoson Stress Cardiovascular Magnetic Resonance Myocardial Perfusion Imaging (2013) (0)
AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment (2009) (0)
219: The Combination of Niacin Extended-Release with Simvastatin Improves Lipid Levels in Treatment-Naive Patients (2008) (0)
Abstract 13009: Low-Dose, Controlled-Release Phentermine/Topiramate Significantly Improves Reynolds 10-Year Risk Score in Obese Women and Men (2010) (0)
Management of Elevated Low-Density Lipoprotein Cholesterol (2006) (0)
Opinions About Statin-Associated Myalgias and Use of Nutraceuticals for Hyperlipidemia Differ Between Primary Care Doctors and Lipid Specialists (2012) (0)
Fenofibrates and the Prevention of Cardiovascular Risk (2006) (0)
Norethindrone Acetate Reduces Triglyceride Elevation Seen With Estrogen Replacement Therapy (2003) (0)
Discordance of Low-Density Lipoprotein Cholesterol With Alternate Lipid Measures in Statin-Treated Men and Women With Mixed Dyslipidemia (2017) (0)
Chapter 25 – Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides (2013) (0)
Favorable Changes in the Factors Affecting Reverse Cholesterol Transport After Feeding Marine Lipids to Hypercholesterolemic Patients (1987) (0)
The PROACTIVE Study and reduction of cardiovascular events in patients with diabetes. (2007) (0)
Long-Term Efficacy of Rosuvastatin and Fenofibric Acid 20 mg/135 mg in Dyslipidemic Patients Initially Treated with Rosuvastatin and Fenofibric Acid 10 mg/135 mg (2010) (0)
A comparison of the lipid-lowering efficacy of simvastatin and flavastatin (1995) (0)
Development and Evaluation of Comprehensive Type II Diabetes Program Utilizing Board Certified Advanced Diabetes Managers in Primary Care (2019) (0)
Perspectives: Benefits of a new, nonsystemic lipid-lowering agent: the clinician's perspective. (2001) (0)
Benefits of a New, Nonsystemic Lipid- Lowering Agent: The Clinician's Perspective (2001) (0)
Lipid Target Attainment by Switching Statin Monotherapy to Fenofibric Acid + Statin in Patients with Mixed Dyslipidemia and at High-/Highest-Risk for Coronary Heart Disease (2011) (0)
Adding Niacin Extended-Release (NER) to Simvastatin Improves Apolipoprotein B (apoB), apoA-I, the apoB:A-I Ratio, and Lipid Goal Attainment in the Highest-Risk Cardiometabolic Patients (2010) (0)
Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. (1997) (0)
Biological therapies for dyslipidemia (2004) (0)
The FIELD Study and reduction of cardiovascular events in patients with diabetes. (2007) (0)
Th-P16:331 Assessment of lipoprotein profiles (Alps study) and antioxidant activity in healthy subjects treated with AGI-1067 (2006) (0)
Lipid sub-fractionation predicts worsening myocardial perfusion reserve in patients with low-density lipoprotein less than 100mg/dL: a regadenoson dardiac magnetic resonance study (2012) (0)
22 Cholesterol lowering efficacy of simvastatin at doses of 80 and 160 mg/d in a new low systemic exposure formulation (1997) (0)
Pitavastatin 4 mg Is Superior to Pravastatin 40 mg in LDL-C Reduction: Results from PREVAIL US Trial in Primary Hyperlipidemia or Mixed Dyslipidemia† (2012) (0)
Th-P16:283 Lipid-altering efficacy and safety of ezetimibe/simvastatin versus rosuvastatin in patients with primary hypercholesterolemia (2006) (0)
New Markers of Vascular Risk (2012) (0)
Abstract 31: A Novel Fluorescence-Based Assay is Used to Investigate the Triglyceride Hydrolytic Activity of Lipases and to Identify Synthetic Peptides With Strong Lipase-Stimulating Activities (2014) (0)
Aspirin Reduces Transient Flushing and Glucose Increases During Therapy with Niacin Extended-Release (2010) (0)
Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. (2004) (0)
Lean red meat and lean white meat in the ncep step i diet (2000) (0)
Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. (2010) (0)
Th-P16:280 Attainment of optimal NCEP ATP III treatment goals in high-risk patients: Dose comparison of ezetimibe/simvastatin and rosuvastatin (2006) (0)
Introduction. U.S. incidence of coronary artery disease. (2008) (0)
Comprar Therapeutic Lipidology | Davidson, Michael | 9781588295514 | Springer (2008) (0)
FADS polymorphisms and plasma levels of omega-3 fatty acids (2016) (0)
Epanova Lowers Apolipoprotein C-III and Increases LDL-Particle Size in Statin-Treated Patients With Mild Hypertriglyceridemia (2013) (0)
Abstract 16873: Safety and Efficacy of Alirocumab in Patients With Atherosclerotic Cardiovascular Disease, Based on Statin Intensity: Pooled Analyses of 5 Placebo-controlled Phase 3 Trials (2016) (0)
Th-P16:281 Evaluation of the ezetimibe/simvastatin tablet compared with atorvastatin or rosuvastatin on C-reactive protein in patients with hypercholesterolemia (2006) (0)
Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey (2002) (0)
What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis? (1998) (0)
4P-1033 In vivo evidence for the alteration of positional specificity of lecithin-cholesterol acyltransferase (LCAT) in humans (2003) (0)
MS94 CHANGES IN PRESCRIPTION PATTERNS FOR EZETIMIBE/SIMVASTATIN, EZETIMIBE + STATIN AND STATIN THERAPIES AND EXPECTED EFFECTS ON LDL-C REDUCTION (2010) (0)
Statin–Fibrate Combination for the Treatment of Dyslipidaemia (2008) (0)
LDL-C REDUCTION AND GOAL ACHIEVEMENT IN PATIENTS WITH DIABETES, METABOLIC SYNDROME, OR NEITHER DISEASE, STRATIFIED BY NCEP CHD RISK CATEGORY (2008) (0)
Abstract 15894: Poor Bioavailability of Ethyl Ester Omega-3's on a Low-Fat Diet is Dramatically Improved With a Free Fatty Acid Formulation (2011) (0)
PO23-756 EFFECTS OF EZETIMIBE/SIMVASTATIN VS. ROSUVASTATIN ON LOWERING OF LDL-CHOLESTEROL AS WELL AS APO-LIPOPROTEIN B, NON-HDL-CHOLESTEROL, OR C-REACTIVE PROTEIN (2007) (0)
Abstract 537: Characterization of the Lipase Stimulating Domain for Apolipoprotein A-V and the Development of a Therapeutic Peptide for the Treatment of Hypertriglyceridemia (2015) (0)
Current understanding and therapeutic approaches to combined hyperlipidemia with low HDL (2011) (0)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2017) (0)
Risk Assessment Is LDL-C Passed Its Prime? : The Emerging Role of Non-HDL, LDL-P, and ApoB in CHD (2013) (0)
The cholesterol-lowering effect and Rebound after withdraw of RYR Cholestin in American subjects with moderate hypercholesterolemia: A multi-center, self-pairing study (2013) (0)
Omega-3 Carboxylic Acids In Severe Hypertriglyceridemia With Triglycerides Greater Than 885mg/Dl (>10mmol/L) (2016) (0)
102: Initial Results of a Home Patient Screening Kit for Diabetes and Dyslipidemia (2008) (0)
Abstract 110: The Separation of Serum Amyloid A from HDL is Mediated by Heparan Sulfate Through Histidine Dependent Interactions: HDL Function is Enhanced but Amyloid-Fibrils may be the “Price to Pay”¼ (2015) (0)
Inherited Lipoprotein Disorders (2011) (0)
A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy of Using Docosahexanoic Acid (Dha) in Subjects with Type IIb Hyperlipidemia (1995) (0)
fficacy and Safety of Torcetrapib , a Novel holesteryl Ester Transfer Protein Inhibitor , n Individuals With Below-Average High-Density ipoprotein Cholesterol Levels on a Background of Atorvastatin ames (2006) (0)
Stuck between Goal Achievement and Evidence-based Medicine (2011) (0)
Treatment with the Combination of Niacin Extended-Release and Simvastatin Reduces Atherogenic Particles in Patients with Mixed Dyslipidemia (2009) (0)
EFFICACY AND SAFETY OF EZETIMIBE AND EZETIMIBE+STATIN IN YOUNG AND ELDERLY PATIENT POPULATIONS (2008) (0)
Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart disease. (2005) (0)
802-6 The Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Heart Disease (1995) (0)
expert roundtable » The Role of CETP Modulation and Inhibition in the Progression of Coronary Heart Disease Moderated (2012) (0)
Abstract 14954: Baseline Apolipoprotein C-III Predicts Triglyceride Lowering by Omega-3 Carboxylic Acids in Patients With Severe Hypertriglyceridemia (2016) (0)
Abstract 15782: Effects of Ezetimibe+Statins and Statin Therapy on Changes in Remnant-lipoprotein Cholesterol (2017) (0)
THE EFFECT OF PCSK9 INHIBITION ON STEROL ABSORPTION IN A COHORT OF REAL WORLD PATIENTS (2017) (0)
Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia (2015) (0)
EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL (2014) (0)
F013: 1-Year treatment with orlistat produces clinically significant weight loss (1998) (0)
218: Niacin Extended-Release/Simvastatin Results in Attainment of Optimal Lipid Levels in Patients Who Failed to Attain These Levels on Statin Monotherapy (2008) (0)
High-dose statins in acute coronary syndromes [1] (multiple letters) (2005) (0)
2.P.286 Rationale and design of a trial to evaluate the impact of continuous combined hormone replacement therapy on the cardiovascular disease risk profile (1997) (0)
On-Treatment Triglyceride Concentration is a Determinant of the Change in LDL Particle Size During Therapy with Omega-3 Free Fatty Acids (2014) (0)
The Role of CETP Modulation and Inhibition in the Progression of Coronary Heart Disease (2020) (0)
Prevalence of Pathogenic Variants of Lipoprotein Metabolism Genes in a Single Lipidology Clinic* (2019) (0)
ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects† (2013) (0)
The ASPEN Study and reduction of cardiovascular events in patients with diabetes. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael H. Davidson?

Michael H. Davidson is affiliated with the following schools:

Michael H. Davidson's Academic­Influence.com Rankings

Michael H. Davidson's Degrees

Why Is Michael H. Davidson Influential?

Michael H. Davidson's Published Works

Published Works

What Schools Are Affiliated With Michael H. Davidson?

Michael H. Davidson's AcademicInfluence.com Rankings